Healthcare (Substance Abuse)

SB 2109 prohibits health insurers and pharmacy benefit managers from requiring or conducting insurance reviews for prescriptions used to treat opioid or alcohol use disorder. Specifically, it blocks reviews for medications containing methadone, buprenorphine, or naltrexone, or for any FDA-approved medication managing opioid withdrawal. The bill directly affects patients seeking addiction treatment and insurers/pharmacy managers handling these prescriptions. It also requires Medicaid managed care organizations to use state-set medical necessity criteria for reviews. The law takes effect upon passage.

Prohibits healthcare insurers from requiring or conducting a review for prescription medicine used to treat alcohol or opioid use disorder containing Methadone, Burenorphine, or Naltrexone, or approved to mitigate opioid withdrawal symptoms.

Establishes a program within the adult correctional institution to permit medication assisted treatment approved by the FDA to be provided for the treatment of opioid use disorder to any incarcerated individual.